This site is intended for U.S. healthcare professionals.

Search

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder Samples

Menu

Close

About PAXLOVIDAbout PAXLOVID

Example of description text sitting alongside header

When to TreatHigh-Risk FactorsMechanism of ActionDosingEfficacy & Real-World EvidenceEfficacy & Real-World Evidence

Example of description text sitting alongside header

EPIC-HR TrialEPIC-HR ResultsReal-World EvidenceSafetySafety

Example of description text sitting alongside header

Adverse ReactionsDrug InteractionsViral ReboundAccess & ResourcesAccess & Resources

Example of description text sitting alongside header

Access & ResourcesDownload Co-Pay CardResourcesRegister for PAXLOVID UpdatesFrequently Asked Questions
Full Prescribing Information and Patient InformationIndication HCP EUA WebsitePatient Website
EPIC-HR ResultsPAXLOVID demonstrated powerful efficacy in the EPIC-HR trial1,2

EPIC-HR was a phase 2/3, randomized, double-blind, placebo-controlled trial in nonhospitalized, symptomatic adults with SARS-CoV-2 infection and ≥1 risk factor for progression to severe disease (N=2113).

Primary endpoint: The proportion of participants with COVID-19–related hospitalization or death from any cause through Day 28

 86% relative risk reduction in COVID-19–related hospitalization or death from any cause through Day 28*
  • Patients treated within 5 days of symptom onset (mITT1)
  • PAXLOVID event rate: 9/977 (0.9%) vs placebo event rate: 64/989 (6.5%)
  • 5.6% absolute risk reduction in hospitalization or death (95% Cl, -7.3 to -4.0; P<0.0001)
86% relative risk reduction in COVID-19–related hospitalization or death from any cause through Day 28*
  • Patients treated within 5 days of symptom onset (mITT1)
  • PAXLOVID event rate: 9/977 (0.9%) vs placebo event rate: 64/989 (6.5%)
  • 5.6% absolute risk reduction in hospitalization or death (95% Cl, -7.3 to -4.0; P<0.0001)
Time to event (mITT1) For patients treated within 3 days of symptom onset (mITT)

89% relative risk reduction in hospitalization or death†

  • PAXLOVID event rate: 5/671 (0.7%) vs placebo event rate: 44/647 (6.8%)
  • -6.1% difference compared with placebo (95% Cl, -8.2 to -4.1; P<0.0001)

 PAXLOVID efficacy was observed across age subgroups Participants ≤60 years of age

saw a 78% relative risk reduction in hospitalization or death

  • PAXLOVID event rate: 8/804 (1.0%) vs placebo event rate: 36/783 (4.6%)
  • -3.66% difference relative to placebo [95% CI, -5.31 to -2.02]
  • Participants ≤60 years of age comprised 80.7% of the mITT1 analysis set (n=1587)
 Participants >60 years of age

saw a 96% relative risk reduction in hospitalization or death

  • PAXLOVID event rate: 1/173 (0.6%) vs placebo event rate: 28/206 (13.6%)
  • -13.13% difference relative to placebo [95% CI, -17.98 to -8.28]
  • Participants >60 years of age comprised 19.3% of the mITT1 analysis set (n=379)
Participants ≤60 years of agesaw a 78% relative risk reduction in hospitalization or death
  • PAXLOVID event rate: 8/804 (1.0%) vs placebo event rate: 36/783 (4.6%)
  • -3.66% difference relative to placebo [95% CI, -5.31 to -2.02]
  • Participants ≤60 years of age comprised 80.7% of the mITT1 analysis set (n=1587)
Participants >60 years of agesaw a 96% relative risk reduction in hospitalization or death
  • PAXLOVID event rate: 1/173 (0.6%) vs placebo event rate: 28/206 (13.6%)
  • -13.13% difference relative to placebo [95% CI, -17.98 to -8.28]
  • Participants >60 years of age comprised 19.3% of the mITT1 analysis set (n=379)

Efficacy was observed across baseline characteristics, regardless of age, symptom onset, BMI, or baseline SARS-CoV-2 serology status

 Next: Real-World EvidenceLoadingEfficacy & Real-World Evidence When to Treat

Treating early may help patients at risk, even if symptoms are mild1

 Find out why Loading*mITT1 analysis set=all treated participants with onset of symptoms within 5 days who at baseline did not receive nor were expected to receive COVID-19 therapeutic mAb treatment.1
†mITT analysis set=all treated participants with onset of symptoms within 3 days who at baseline did not receive nor were expected to receive COVID-19 therapeutic mAb treatment.BMI=body mass index; CI=confidence interval; EPIC-HR=Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients; mAb=monoclonal antibody; mITT=modified intent-to-treat; SARS-CoV-2=severe acute respiratory syndrome coronavirus 2.References:PAXLOVID Prescribing Information. Pfizer Inc.; 2025.Data on File. CSR. Pfizer Inc.; 2023.

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-C1D-USA-1822
Important Safety Information
 WARNING: SIGNIFICANT DRUG INTERACTIONS WITH PAXLOVID
  • PAXLOVID includes ritonavir, a strong CYP3A inhibitor, which may lead to greater exposure of certain concomitant medications, resulting in potentially severe, life-threatening, and/or fatal events
  • Prior to prescribing PAXLOVID: 1) Review all medications taken by the patient to assess for potential drug-drug interactions with a strong CYP3A inhibitor like PAXLOVID and 2) Determine if concomitant medications require a dose adjustment, interruption, and/or additional monitoring
  • Consider the benefit of PAXLOVID treatment in reducing hospitalization and death, and whether the risk of potential drug-drug interactions for an individual patient can be appropriately managed
PAXLOVID is contraindicated in patients with a history of clinically significant hypersensitivity reactions (eg, toxic epidermal necrolysis or Stevens-Johnson syndrome) to its active ingredients (nirmatrelvir or ritonavir) or any other components of the product. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue PAXLOVID and initiate appropriate medications and/or supportive care. PAXLOVID is contraindicated with drugs that are primarily metabolized by CYP3A and for which elevated concentrations are associated with serious and/or life-threatening reactions and drugs that are strong CYP3A inducers where significantly reduced nirmatrelvir or ritonavir plasma concentrations may be associated with the potential for loss of virologic response and possible resistance. There are certain other drugs for which concomitant use with PAXLOVID should be avoided and/or dose adjustment, interruption, or therapeutic monitoring is recommended. Drugs listed here are a guide and not considered a comprehensive list of all drugs that may be contraindicated with PAXLOVID. The healthcare provider should consult other appropriate resources such as the prescribing information for the interacting drug for comprehensive information on dosing or monitoring with concomitant use of a strong CYP3A inhibitor like PAXLOVID. Drugs that are primarily metabolized by CYP3A for which elevated concentrations are associated with serious and/or life-threatening reactions:
  • Alpha 1-adrenoreceptor antagonist: alfuzosin
  • Antianginal: ranolazine
  • Antiarrhythmic: amiodarone, dronedarone, flecainide, propafenone, quinidine
  • Anti-gout: colchicine (in patients with renal and/or hepatic impairment)
  • Antipsychotics: lurasidone, pimozide
  • Benign prostatic hyperplasia agents: silodosin
  • Cardiovascular agents: eplerenone, ivabradine
  • Ergot derivatives: dihydroergotamine, ergotamine, methylergonovine
  • HMG-CoA reductase inhibitors: lovastatin, simvastatin (these drugs can be temporarily discontinued to allow PAXLOVID use)
  • Immunosuppressants: voclosporin
  • Microsomal triglyceride transfer protein inhibitor: lomitapide
  • Migraine medications: eletriptan, ubrogepant
  • Mineralocorticoid receptor antagonists: finerenone
  • Opioid antagonists: naloxegol
  • PDE5 inhibitor: sildenafil (Revatio®) when used for pulmonary arterial hypertension
  • Sedative/hypnotics: triazolam, oral midazolam
  • Serotonin receptor 1A agonist/serotonin receptor 2A antagonist: flibanserin
  • Vasopressin receptor antagonists: tolvaptan

Drugs that are strong CYP3A inducers: PAXLOVID cannot be started immediately after discontinuation of any of the following medications due to the delayed offset of the recently discontinued CYP3A inducer:

  • Anticancer drugs: apalutamide, enzalutamide
  • Anticonvulsant: carbamazepine, phenobarbital, primidone, phenytoin
  • Antimycobacterials: rifampin, rifapentine
  • Cystic fibrosis transmembrane conductance regulator potentiators: lumacaftor/ivacaftor
  • Herbal Products: St. John’s Wort (hypericum perforatum)
 Risk of Serious Adverse Reactions Due to Drug Interactions: Initiation of PAXLOVID, which contains ritonavir, a strong CYP3A inhibitor, in patients receiving medications metabolized by CYP3A or initiation of medications metabolized by CYP3A in patients already receiving PAXLOVID, may increase plasma concentrations of medications metabolized by CYP3A. Medications that induce CYP3A may decrease concentrations of PAXLOVID. These interactions may lead to:
  • Clinically significant adverse reactions, potentially leading to severe, life-threatening, or fatal events from greater exposures of concomitant medications
  • Loss of therapeutic effect of PAXLOVID and possible development of viral resistance
Severe, life-threatening, and/or fatal adverse reactions due to drug interactions have been reported in patients treated with PAXLOVID. The most commonly reported concomitant medications resulting in serious adverse reactions were calcineurin inhibitors (eg, tacrolimus, cyclosporine), followed by calcium channel blockers. Hepatotoxicity: Hepatic transaminase elevations, clinical hepatitis, and jaundice have occurred in patients receiving ritonavir. Therefore, caution should be exercised when administering PAXLOVID to patients with pre-existing liver diseases, liver enzyme abnormalities, or hepatitis. Because nirmatrelvir is coadministered with ritonavir, there may be a risk of HIV-1 developing resistance to HIV protease inhibitors in individuals with uncontrolled or undiagnosed HIV-1 infection. The most common adverse reactions in the PAXLOVID group (≥1%) that occurred at a greater frequency than in the placebo group were dysgeusia (5% and <1%, respectively) and diarrhea (3% and 2%, respectively). The following adverse reactions have been identified during use of PAXLOVID under Emergency Use Authorization: Immune System Disorders: Anaphylaxis, hypersensitivity reactions Skin and Subcutaneous Tissue Disorders: Toxic epidermal necrolysis, Stevens-Johnson syndrome Nervous System Disorders: Headache Vascular Disorders: Hypertension Gastrointestinal Disorders: Abdominal pain, nausea, vomiting General Disorders and Administration Site Conditions: Malaise PAXLOVID is a strong inhibitor of CYP3A, and an inhibitor of CYP2D6, P-gp, and OATP1B1. Coadministration of PAXLOVID with drugs that are primarily metabolized by CYP3A and CYP2D6 or are transported by P-gp or OATP1B1 may result in increased plasma concentrations of such drugs and increase the risk of adverse events. Coadministration with other CYP3A substrates may require a dose adjustment or additional monitoring.Pregnancy: Available data on the use of nirmatrelvir during pregnancy are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Published observational studies on ritonavir use in pregnant women have not identified an increase in the risk of major birth defects. Published studies with ritonavir are insufficient to identify a drug-associated risk of miscarriage. There are maternal and fetal risks associated with untreated COVID-19 in pregnancy.Lactation: Nirmatrelvir and ritonavir are present in human breast milk in small amounts (less than 2%). There are no available data on the effects of nirmatrelvir or ritonavir on the breastfed infant or on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for PAXLOVID and any potential adverse effects on the breastfed infant from PAXLOVID or from the underlying maternal condition.Contraception: Use of ritonavir may reduce the efficacy of combined hormonal contraceptives. Advise patients using combined hormonal contraceptives to use an effective alternative contraceptive method or an additional barrier method of contraception. Pediatrics: The optimal dose of PAXLOVID has not been established in pediatric patients. Renal impairment increases nirmatrelvir exposure. Reduce the PAXLOVID dosage in patients with moderate renal impairment (eGFR ≥30 to <60 mL/min). Reduce the dose and dose frequency in patients with severe renal impairment (eGFR <30 mL/min), including those requiring hemodialysis. On days when patients undergo hemodialysis, the PAXLOVID dose should be administered after hemodialysis. Prescriptions should specify the numeric dose of each active ingredient within PAXLOVID. Providers should counsel patients about renal dosing instructions. PAXLOVID is not recommended for use in patients with severe hepatic impairment (Child-Pugh Class C). Please see Full Prescribing Information, including BOXED WARNING and Patient Information IndicationINDICATIONPAXLOVID is indicated for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults who are at high risk for progression to severe COVID-19, including hospitalization or death.Limitations of UsePAXLOVID is not approved for use as pre-exposure or post-exposure prophylaxis for prevention of COVID-19.Please see Full Prescribing Information, including BOXED WARNING and Patient Information
Indication PAXLOVID is indicated for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults who are at high risk for progression to severe COVID-19, including hospitalization or death.

Limitations of Use

PAXLOVID is not approved for use as pre-exposure or post-exposure prophylaxis for prevention of COVID-19.

Please see Full Prescribing Information, including BOXED WARNING and Patient Information